Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
aducanumab
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan
Biogen and Eisai have jointly developed three experimental drugs for Alzheimer’s